Literature DB >> 16082627

Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia.

S V Kocheril1, B E Appleton, E C Somers, E A Kazerooni, K R Flaherty, F J Martinez, B H Gross, L J Crofford.   

Abstract

OBJECTIVE: To compare disease progression and mortality between idiopathic interstitial pneumonia (IIP) and interstitial lung disease (ILD) due to connective tissue diseases (CTD) including scleroderma, rheumatoid arthritis, systemic lupus, polymyositis, dermatomyositis, Sjögren's syndrome, and mixed CTD.
METHODS: A case-control study of patients with CTD-ILD (n = 46) and IIP controls (n = 51), seen at the University of Michigan between July 1,1998 and June 30,1999 and followed until March 30, 2002, was conducted. Survival analysis and Cox regression were performed to estimate survival, accounting for demographic and clinical parameters, including pulmonary function tests and high resolution computed tomography (HRCT) diagnosis and scoring.
RESULTS: Median followup time was 4.4 person-years. Five-year survival in the IIP group was 51.9% (95% confidence interval [95% CI] 30.8-69.4) versus 43.4% (95% CI 21.1-63.9) in the CTD-ILD group. There were no significant differences among HRCT diagnostic categories between IIP and CTD-ILD. A fibrotic score > or = 2 was associated with decreased survival among the entire group. Age at diagnosis and most recent forced vital capacity were significant predictors of mortality when adjusted for IIP versus CTD-ILD diagnosis, sex, and interstitial score.
CONCLUSION: Contrary to expectation, CTD-ILD compared with IIP appears to be associated with a worse prognosis when adjusted for age. A higher fibrotic score is suggestive of decreased survival.

Entities:  

Mesh:

Year:  2005        PMID: 16082627     DOI: 10.1002/art.21322

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  24 in total

1.  Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis.

Authors:  D J Lederer; S M Arcasoy; R G Barr; J S Wilt; E Bagiella; F D'Ovidio; J R Sonett; S M Kawut
Journal:  Am J Transplant       Date:  2006-07-26       Impact factor: 8.086

2.  Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease.

Authors:  Jeffrey J Swigris; Janelle Yorke; David B Sprunger; Christopher Swearingen; Theodore Pincus; Roland M du Bois; Kevin K Brown; Aryeh Fischer
Journal:  Respir Med       Date:  2010-05-14       Impact factor: 3.415

3.  Connective tissue disease associated interstitial pneumonia: a challenge for both rheumatologists and pulmonologists.

Authors:  Sarah Geerts; Wim Wuyts; Ellen De Langhe; Jan Lenaerts; Jonas Yserbyt
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

4.  Clinical characteristics and survival in idiopathic pulmonary fibrosis and connective tissue disease-associated usual interstitial pneumonia.

Authors:  Esam H Alhamad
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

5.  Quantitative diagnosis of connective tissue disease-associated interstitial pneumonia using thoracic computed tomography images.

Authors:  Nobuko Tosaka Ozuno; Hokuto Akamatsu; Hiroshi Takahashi; Naoko Fujii; Shunji Yoshida
Journal:  Clin Rheumatol       Date:  2015-10-31       Impact factor: 2.980

6.  Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.

Authors:  Justin M Oldham; Cathryn Lee; Eleanor Valenzi; Leah J Witt; Ayodeji Adegunsoye; Scully Hsu; Lena Chen; Steven Montner; Jonathan H Chung; Imre Noth; Rekha Vij; Mary E Strek
Journal:  Respir Med       Date:  2016-11-04       Impact factor: 3.415

Review 7.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

8.  Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome.

Authors:  V Goëb; V Salle; P Duhaut; F Jouen; A Smail; J-P Ducroix; F Tron; X Le Loët; O Vittecoq
Journal:  Clin Exp Immunol       Date:  2007-02-07       Impact factor: 4.330

9.  Rheumatoid lung disease.

Authors:  Kevin K Brown
Journal:  Proc Am Thorac Soc       Date:  2007-08-15

10.  Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.

Authors:  Brent W Kinder; Cyrus Shariat; Harold R Collard; Laura L Koth; Paul J Wolters; Jeffrey A Golden; Ralph J Panos; Talmadge E King
Journal:  Lung       Date:  2010-04       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.